Intellia Therapeutics Has Initiated HAELO Phase 3 Study Of NTLA-2002 For Hereditary Angioedema; Patient Screening Is Active
Portfolio Pulse from Benzinga Newsdesk
Intellia Therapeutics has started the HAELO Phase 3 study for NTLA-2002, a single-dose treatment for hereditary angioedema. This marks Intellia's second in vivo candidate to reach late-stage clinical development.
October 07, 2024 | 11:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Intellia Therapeutics has initiated a Phase 3 study for NTLA-2002, a treatment for hereditary angioedema. This advancement highlights the progress of Intellia's gene editing platform.
The initiation of a Phase 3 study for NTLA-2002 is a significant milestone for Intellia Therapeutics, indicating progress in their gene editing platform. Successful advancement in clinical trials can lead to increased investor confidence and potential future revenue streams, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90